Brief: Ikena Oncology Inc Says In April 2022, Co Advanced To Stage Two Of Nivolumab Combination Expansion Cohort In Phase 1B Clinical Trial Of Ik-175

ImageneBio

06/04/2022 12:08

April 6 (Reuters) - Ikena Oncology Inc  IKNA.O :
    * IKENA ONCOLOGY INC - IN APRIL 2022, CO ADVANCED TO STAGE
TWO OF
NIVOLUMAB COMBINATION EXPANSION COHORT IN PHASE 1B CLINICAL
TRIAL OF IK-175
    * IKENA ONCOLOGY INC - COMPANY PLANS TO SUBMIT INITIAL
CLINICAL
DATA FROM THIS TRIAL TO AN ONCOLOGY CONFERENCE IN SECOND HALF OF
2022

Source: [ID: https://bit.ly/3J8lft2]
Further company coverage:  IKNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))